Inventor · disambiguated record
Claresa Levetan
Also filed as: LEVETAN CLARESA · LEVETAN CLARESA S
18 granted patents·20 pending applications·145 citations·filing 2006–2024
95Inventor score
Top patents by PatentIndex Score
38 records- 0193US9321812B2Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptideLEVETAN CLARESA·Filed 2014·Granted Apr 26, 2016·7 cites·16 claims
- 0293US8816047B2Compositions and methods of using proislet peptides and analogs thereofLEVETAN CLARESA S·Filed 2008·Granted Aug 26, 2014·28 cites·19 claims
- 0393US7393919B2Peptides, derivatives and analogs thereof, and methods of using sameCURE DM INC·Filed 2006·Granted Jul 1, 2008·26 cites·11 claims
- 0492US7989415B2Peptides, derivatives and analogs thereof, and methods of using sameCUREDM GROUP HOLDINGS LLC·Filed 2009·Granted Aug 2, 2011·11 cites·32 claims
- 0591US10016482B2Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 10, 2018·3 cites·3 claims
- 0691US10010580B2Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 3, 2018·3 cites·3 claims
- 0791US10010577B2Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 3, 2018·3 cites·3 claims
- 0891US7714103B2Peptides, derivatives and analogs thereof, and methods of using sameCUREDM INC·Filed 2008·Granted May 11, 2010·13 cites·24 claims
- 0989US10010578B2Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 3, 2018·3 cites·3 claims
- 1089US9511110B2Generation of new pancreatic beta cellsLEVETAN CLARESA·Filed 2012·Granted Dec 6, 2016·6 cites·15 claims
- 1188US8383578B2Peptides, derivatives and analogs thereof, and methods of using sameCUREDM GROUP HOLDINGS LLC·Filed 2011·Granted Feb 26, 2013·4 cites·20 claims
- 1287US8785400B2Methods and compositions relating to islet cell neogenesisLEVETAN CLARESA S·Filed 2007·Granted Jul 22, 2014·12 cites·16 claims
- 1387US8211430B2Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditionsLEVETAN CLARESA S·Filed 2006·Granted Jul 3, 2012·13 cites·12 claims
- 1486US10010579B2Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptideLEVETAN CLARESA·Filed 2016·Granted Jul 3, 2018·3 cites·3 claims
- 1586US8911776B2Generation of new pancreatic beta cellsLEVETAN CLARESA·Filed 2012·Granted Dec 16, 2014·4 cites·13 claims
- 1682US9133440B2Generation of new pancreatic beta cellsLEVETAN CLARESA·Filed 2012·Granted Sep 15, 2015·3 cites·10 claims
- 1782US8808689B1Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agentLEVETAN CLARESA·Filed 2013·Granted Aug 19, 2014·3 cites·14 claims
- 1871US2015056167A1Peptides, derivatives and analogs thereof, and methods of using sameCUREDM GROUP HOLDINGS LLC·Filed 2014·Application pending·0 cites
- 1970US2018125933A1Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptideLEVETAN CLARESA·Filed 2017·Application pending·0 cites
- 2067US8829158B2Peptides, derivatives and analogs thereof, and methods of using sameCUREDM GROUP HOLDINGS LLC·Filed 2013·Granted Sep 9, 2014·0 cites·15 claims
- 2166US2025099544A1Treatment of Type 1 Diabetes and Other Conditions Using the Gut MicrobiomeLEVETAN CLARESA·Filed 2024·Application pending·0 cites
- 2265US2020054716A1Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapiesLEVETAN CLARESA·Filed 2019·Application pending·0 cites
- 2363US2015086548A1Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related ConditionsCUREDM GROUP HOLDINGS LLC·Filed 2014·Application pending·0 cites
- 2463US2009142338A1Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related ConditionsCUREDM INC·Filed 2007·Application pending·0 cites
- 2559US2014235552A1Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agentLEVETAN CLARESA·Filed 2013·Application pending·0 cites
- 2658US2019142901A1Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapiesLEVETAN CLARESA·Filed 2017·Application pending·0 cites
- 2756US2021371478A1Generation of brain and spinal cord neurons, cardiac myocytes, and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptorLEVETAN CLARESA·Filed 2021·Application pending·0 cites
- 2852US2015018272A1Compositions and methods of using proislet peptides and analogs thereofCUREDM GROUP HOLDINGS LLC·Filed 2014·Application pending·0 cites
- 2952US2019328839A1Treatment of Type 1 Diabetes and Other Conditions Using the Gut MicrobiomeLEVETAN CLARESA·Filed 2019·Application pending·0 cites
- 3051US2021299226A1Method of treating and preventing coronaviruses with low dosage interferon beta-1a as a th17 inhibitorLEVETAN CLARESA·Filed 2020·Application pending·0 cites
- 3151US2015010508A1Methods And Compositions Relating To Islet Cell NeogenesisCUREDM GROUP HOLDINGS LLC·Filed 2014·Application pending·0 cites
- 3251US2015174111A1Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agentLEVETAN CLARESA·Filed 2015·Application pending·0 cites
- 3350US2011082080A1Compositions and methods of using the human proislet peptide receptorCUREDM GROUP HOLDINGS LLC·Filed 2008·Application pending·0 cites
- 3450US2014234405A1Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agentLEVETAN CLARESA·Filed 2013·Application pending·0 cites
- 3546US2019330289A1Generation of brain and spinal cord neurons, cardiac myocytes, renal nephrons and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptorLEVETAN CLARESA·Filed 2019·Application pending·0 cites
- 3644US2014120560A1Generation of new pancreatic beta cellsLEVETAN CLARESA·Filed 2012·Application pending·0 cites
- 3742US2013216545A1Early Diagnosis and Novel Treatment of CancerLEVETAN CLARESA·Filed 2012·Application pending·0 cites
- 3841US2017081375A1Generation of brain and spinal cord neurons, cardiac myocytes, renal nephrons and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptorLEVETAN CLARESA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Claresa Levetan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →